TSX Shariah screener · October 2026
Curaleaf Holdings, Inc.
Is Curaleaf Holdings, Inc. (CURA) Halal?
Curaleaf Holdings, Inc. · TSX: CURA · Healthcare
Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.
The short answer
Curaleaf Holdings, Inc. (TSX: CURA) is a FAIL. The business gate fails: Curaleaf is a vertically integrated cannabis multi-state operator — 100% of revenue is cannabis, and the company itself states only about 60% of its US business is medical, i.e. roughly 40% is adult-use recreational cannabis, far above the ~5% threshold for a prohibited segment. The financial gates pass on their own: interest-bearing debt of US$611.5M is about 21.4% of the ~US$2.86B market cap (264.9M shares × C$15.38, September 29, 2026), under the ~33% ceiling, and separately disclosed interest income of US$149K is about 0.04% of Q2 2026 revenue, under the ~5% ceiling — but the business screen is decisive. Musaffa independently rates it not halal. This is a rules-based screen, not a religious ruling.
Gate 1 — Business activity: FAIL
Curaleaf Holdings, Inc. is a vertically integrated cannabis multi-state operator: it cultivates, manufactures, wholesales, and retails cannabis through 170+ dispensaries across about 18 US states, plus international operations (UK, Germany, Poland, and others). Q2 2026 revenue was US$340.1M (domestic retail US$224.4M, domestic wholesale US$64.0M, international retail US$16.4M, international wholesale US$31.9M) — all of it cannabis. The company itself states about 60% of its US business is medical, i.e. roughly 40% is adult-use recreational cannabis — far above the ~5% threshold for a prohibited segment. (Curaleaf graduated from the CSE to the TSX on December 14, 2023 and trades as TSX: CURA in CAD plus OTCQX: CURLF in USD.) The business gate fails, and that is decisive.
Gate 2 — Debt and cash: PASS (but moot)
Outstanding interest-bearing debt at June 30, 2026 (Q2 2026 results) was US$611.5M (net of unamortized debt discounts and deferred financing fees). Against a market cap of ~US$2.86B (264.9M shares × C$15.38, September 29, 2026, TSX; converted at ~0.70 USD/CAD), that is about 21.4% — under the ~33% ceiling. Cash and cash equivalents (including restricted cash) were US$107.0M, about 3.7% of market cap — under the ~33% guideline. The debt gate passes on its own, but it does not rescue the failed business screen.
Gate 3 — Non-compliant income: PASS (but moot)
The Q2 2026 condensed statements of operations separately disclose “Interest income” of US$149K — not netted against expense — against revenue of US$340.1M, about 0.04%, under the ~5% ceiling. (Six-month interest income was US$361K on US$664.3M revenue.) The income gate passes on its own, but it does not rescue the failed business screen.
BDS screen
Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.
No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).
Moral screen
Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.
- Israeli military business
- No findings published.
- US military business
- No findings published.
- Weapons manufacturing & arms trade
- No findings published.
Key figures used
- FAIL — business gate fails decisively (October 2026 screen)
- Business: vertically integrated cannabis MSO — cultivation, manufacturing, wholesale, 170+ dispensaries (~18 US states) + international; 100% of revenue is cannabis; ~40% of US business is adult-use recreational (company disclosure: ~60% medical)
- Debt: US$611.5M outstanding (Jun 30, 2026) ≈ 21.4% of ~US$2.86B market cap vs ~33% ceiling (passes on its own)
- Income: ≈0.04% — separately disclosed “Interest income” US$149K ÷ Q2 2026 revenue US$340.1M vs ~5% ceiling (passes on its own)
- Cash: US$107.0M (incl. restricted) ≈ 3.7% of market cap
- Third-party: Musaffa rates CURLF not halal (AAOIFI, Oct 2026) — agrees with our FAIL; no public Zoya/ShariaPortfolio coverage found
- Caveat: Q3 2026 results expected ~November 3, 2026 — figures should be refreshed then
Halal alternatives in this sector
CURA did not pass the screen. These companies in the same sector passed:
- Cipher Pharmaceuticals Inc. PASS
- Extendicare Inc. PASS
- Knight Therapeutics Inc. PASS
Frequently asked questions
Is Curaleaf Holdings (CURA) halal?
Our October 2026 screen gives Curaleaf Holdings, Inc. (TSX: CURA) a FAIL. The business gate fails: Curaleaf is a vertically integrated cannabis multi-state operator — 100% of its revenue is cannabis, and the company itself states only about 60% of its US business is medical, i.e. roughly 40% is adult-use recreational cannabis, far above the 5% threshold for a prohibited segment. The financial gates pass (debt about 21.4% of market cap; interest income about 0.04% of revenue), but the business screen is decisive. Musaffa independently rates it not halal. This is a rules-based screen, not a religious ruling.
What does Curaleaf Holdings do?
Curaleaf is a vertically integrated cannabis multi-state operator: it cultivates, manufactures, wholesales, and retails cannabis through 170+ dispensaries across about 18 US states, plus international operations (UK, Germany, Poland, and others). Q2 2026 revenue was US$340.1M (domestic retail US$224.4M, domestic wholesale US$64.0M, international retail US$16.4M, international wholesale US$31.9M). All revenue is cannabis.
How much debt does Curaleaf Holdings have?
At June 30, 2026 (Q2 2026 results), outstanding interest-bearing debt was US$611.5M (net of unamortized debt discounts and deferred financing fees). Against a market cap of ~US$2.86B (264.9M shares × C$15.38, September 29, 2026, TSX; converted at ~0.70 USD/CAD), that is about 21.4% — under the ~33% ceiling, so the debt gate passes on its own. Cash and equivalents (including restricted cash) were US$107.0M, about 3.7% of market cap.
Does Curaleaf earn interest income?
Very little, and it is separately disclosed. The Q2 2026 condensed statements of operations carry an “Interest income” line of US$149K (not netted against expense), against revenue of US$340.1M — about 0.04%, under the ~5% ceiling. The income gate passes on its own.
What do third-party Shariah screeners say about Curaleaf?
Musaffa covers CURLF and currently rates it not halal under AAOIFI methodology (page current as of October 2026), which agrees with our FAIL. No public Zoya or ShariaPortfolio coverage page for CURA/CURLF was found — their screening data sits behind app logins, so their status is honestly unknown rather than assumed.
Sources
- Curaleaf Holdings, Inc. — Q2 2026 results press release (Aug 5, 2026; condensed consolidated statements: debt US$611.5M, interest income US$149K, revenue US$340.1M)
- Curaleaf Holdings, Inc. — fact sheet (~60% of US business is medical)
- Curaleaf Holdings, Inc. — Q1 2026 investor deck
- Musaffa — CURLF stock page (rates not halal, AAOIFI; current October 2026)
- Stockwatch — Curaleaf TSX graduation (Dec 14, 2023)
- Finnhub — Curaleaf Holdings, Inc. (CURA.TO) quote, TSX (C$15.38, September 29, 2026)
Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).